• BioNexus Gene Lab posted a net loss attributable to common shareholders of USD 3 million for fiscal 2025, widening from the prior year.
• Revenue fell 21.9% to USD 7.4 million.
• Operating loss widened to USD 3 million.
• Working capital slipped to USD 4.9 million at Dec. 31, 2025, while net cash used in operating activities narrowed to USD 1.8 million.
• Management cited lower sales volume at Chemrex, higher holding-company general and administrative expenses, and financing and strategic transactions tied to Fidelion and ARC; plans include liquidity management, Chemrex performance improvement, internal control remediation, and pursuing external financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-002218), on April 14, 2026, and is solely responsible for the information contained therein.